



Vaccination Strategies as We Face Another Year of the COVID-19 Pandemic

Guest Editor:

Prof. Dr. Hanna Czajka

1. College of Medical Sciences,
University of Rzeszów, 35-315
Rzeszów, Poland
2. Infectious Diseases Outpatient
Clinic, St. Louis Regional
Specialised Children's Hospital,
31-503 Cracow, Poland

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

We are now in the third year of the COVID-19 pandemic, and we are constantly seeking solutions to ensure effective prevention of this disease. Ongoing clinical trials are providing new data on the safety and efficacy of COVID-19 vaccination in different age groups, optimal vaccination schedules, and timing of subsequent booster doses.

Particular attention should be paid to patients in risk groups who may have reduced vaccine response. Hence, it is necessary to consider the possibility of administering a third dose of basic vaccination to these patients and to determine the timing of booster doses.

During the pandemic period, there was a delay and reduction in the number of vaccinations being carried out. Hence, there is a need to immediately compensate for delays in the implementation of immunizations according to national vaccination programs, to introduce widely available coadministration of vaccines with COVID-19 vaccination. It is also necessary to extend the use of the influenza vaccine.

For this Special Issue, we discuss strategies for vaccinating against COVID-19 as well as combining this vaccination with the prevention of other infectious diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com